Novo Nordisk (NOVOB DC) confirms that it received an untitled letter from the FDA concerning a TV commercial for the WeGovy pill

Novo Nordisk's acknowledgment of receiving an untitled letter from the FDA regarding its WeGovy TV commercial raises regulatory scrutiny over its marketing claims.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily US Earnings Estimates - 10th February 2026: CVS, KO, SPGI, GILD, WELL, AZN

Anthropic is reportedly assembling a veteran team and considering securing at least 10GW of capacity over the next several years, according to The Information

Novo Nordisk (NOVOB DC) confirms that it received an untitled letter from the FDA concerning a TV commercial for the WeGovy pill

French Government Advisory Body issues report on China, which recommends ways to neutralise competitiveness gaps; including implementation of a 30% general tariff, or a depreciation of the Euro by 20-30% vs the Renminbi

US sells 3-month bills at a high rate of of 3.60%, B/C 2.76x; Sells 6-month bills at a high rate of 3.500%, B/C 2.76x

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could impact investor sentiment as it signals potential challenges in communication strategies and compliance, which may lead to greater volatility in the stock. Traders should consider how this situation might affect broader perceptions of the company’s risk profile and market stability.

Related headlines

The whole workspace, free to try.

Try it free